Financial Performance - The company's revenue for the year ended December 31, 2025, was RMB 1,623,177,000, a decrease of 53.5% compared to RMB 3,488,094,000 in 2024[3]. - Gross profit for the same period was RMB 775,080,000, down 10.0% from RMB 861,672,000 in 2024[3]. - Operating loss increased to RMB (853,301,000), a rise of 126.9% from RMB (376,141,000) in the previous year[3]. - The adjusted net loss (non-IFRS measure) was RMB (182,129,000), up 56.9% from RMB (116,093,000) in 2024[3]. - The company reported a net loss of RMB 968.5 million for the reporting period, an increase of 97.1% year-on-year, primarily due to losses from divested subsidiaries and one-time provisions[17]. - The company recorded a net loss of approximately RMB 491.4 million for the fiscal year ending December 31, 2024, increasing by 97.1% to approximately RMB 968.5 million for the fiscal year ending December 31, 2025, primarily due to losses from the sale of subsidiaries[51]. - The company reported a basic loss per share of RMB 1.52 for the year ended December 31, 2025, compared to RMB 0.89 for 2024, based on a weighted average of 609,853,000 shares outstanding[114]. Revenue Breakdown - Revenue from in-hospital solutions was RMB 1,188.8 million, a decrease of 55.7% from RMB 2,683.3 million in the previous year[23]. - Revenue from outpatient solutions dropped by 46.0% from approximately RMB 804.8 million in 2024 to approximately RMB 434.4 million in 2025, primarily due to a strategic focus on AI-assisted pharmacy solutions and P2M solutions[39]. - Revenue from the P2M solution reached RMB 419.1 million, a significant increase of 46.6% compared to RMB 286.0 million in the previous year[21]. - The P2M solutions generated total revenue of RMB 504.5 million as of December 31, 2025, representing a substantial increase of 57.5% compared to December 31, 2024, achieving profitability[14]. - Revenue from subscription solutions (precision marketing) was RMB 253.9 million, a decrease of 9.9% from RMB 281.9 million in the previous year[23]. Operational Metrics - The average daily online effective prescription volume exceeded one million during the reporting period[7]. - The number of registered users on the company's pharmacy platform reached approximately 61.4 million, with online prescriptions totaling 371.6 million, reflecting a year-on-year growth of 40.5%[27]. - The company has connected over 18,000 hospitals, capturing 40% of the top 100 hospitals in China, with a penetration rate of over 30% in tertiary public hospitals[6]. - The company has installed its AI-driven pharmacy platform in 275,613 pharmacies, representing approximately 40% of the total pharmacies in China[7]. - The number of pharmacies using the AI-driven pharmacy platform increased by 13.6% to 275,613 in 2025[31]. Cost and Expenses - The total cost of goods sold was RMB 754,616,000 in 2025, significantly lower than RMB 2,565,680,000 in 2024, representing a decrease of approximately 70.7%[109]. - Sales cost decreased by 67.7% to approximately RMB 848.1 million in 2025, outpacing the revenue decline due to a shift towards higher-margin solutions[40]. - Personnel-related costs for the year ending December 31, 2025, amounted to approximately RMB 786.5 million, a decrease from RMB 842.6 million for the year ending December 31, 2024[69]. - The company's employee compensation expenses decreased to RMB 290,697,000 in 2025 from RMB 355,251,000 in 2024, a decline of approximately 18.1%[107]. Cash Flow and Liquidity - The company achieved a net cash inflow from operating activities of RMB 66.8 million in 2025, compared to a net cash outflow of RMB 148.4 million in the same period of 2024, indicating a necessary transformation[13]. - Cash and cash equivalents as of December 31, 2025, were approximately RMB 267.6 million, down from RMB 304.8 million as of December 31, 2024[56]. - The company's debt-to-asset ratio increased to 51.1% as of December 31, 2025, from 42.1% as of December 31, 2024, primarily due to a faster decline in total assets compared to total liabilities[63]. Strategic Focus and Future Plans - The company is focusing on a P2M strategy to achieve stable cash flow and profitability in the short term, with a long-term goal of monetizing data assets[13]. - The company plans to continue investing in product and technology innovation, focusing on medical AI models to strengthen its market position[36]. - The company aims to enhance the healthcare ecosystem's efficiency through technology and continues to build digital infrastructure for chronic disease management[9]. - The company has received sales approval for an important P2M pipeline product, which is expected to enhance long-term market expansion and profitability[15]. Corporate Governance and Compliance - The audit committee has reviewed the accounting policies and consolidated financial information for the year ending December 31, 2025[75]. - There were no significant lawsuits or arbitrations involving the company during the reporting period[78]. - The company did not engage in any significant investments or acquisitions during the year ended December 31, 2025[59][60]. Employee and Workforce - The company employed a total of 887 employees as of December 31, 2025, with the majority located in Hangzhou, Shanghai, and other offices in China[67]. - As of December 31, 2025, the total number of employees is 887, with 703 in sales and marketing, 66 in R&D, 47 in general and administration, and 71 in other functions[68].
智云健康(09955) - 2025 - 年度业绩